Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
bioAffinity TechnologiesBIAFW -27.12%44 Debt-to-Equity is 0.38 as of Jun. 2026, which is 217% above its 10-year median of 0.12. GuruFocus rates BIAFW with a GF Score™ of 44/100. The stock has 3 warning signs investors should review. Among 179 Medical Diagnostics & Research companies, bioAffinity Technologies ranks worse than 56.98% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for bioAffinity Technologies's Debt-to-Equity or its related term are showing as below:
BIAFW'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.72 Med: 0.12 Max: 0.93
Current: 0.38
During the past 6 years, the highest Debt-to-Equity Ratio of bioAffinity Technologies was 0.93. The lowest was -0.72. And the median was 0.12.
BIAFW's Debt-to-Equity is ranked worse than 56.98% of 179
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.3
vs BIAFW: 0.38
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
bioAffinity Technologies Debt-to-Equity Related Terms
bioAffinity Technologies Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BIAFW vs ISPC, IVRO, IDTA: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, bioAffinity Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
bioAffinity Technologies Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where bioAffinity Technologies's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
bioAffinity Technologies (BIAFW) has a Debt-to-Equity of 0.38 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on bioAffinity Technologies and its competitors. This is 217% above median its historical median of 0.12. According to the industry distribution chart, bioAffinity Technologies ranks #102 out of 179 companies in the Medical Diagnostics & Research industry, placing it in the top 57%.
Is bioAffinity Technologies' Debt-to-Equity too high?
bioAffinity Technologies' current Debt-to-Equity of 0.38 is 217% above median its 10-year median of 0.12. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.30. bioAffinity Technologies' value of 0.38 is 26.7% above this industry median. Based on the distribution chart, bioAffinity Technologies ranks #102 out of 179 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, bioAffinity Technologies has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does bioAffinity Technologies' Debt-to-Equity compare to ISPC and IVRO?
According to the Medical Diagnostics & Research industry distribution chart, bioAffinity Technologies ranks #102 out of 179 companies for Debt-to-Equity. This places bioAffinity Technologies in the lower half of its industry. The industry median Debt-to-Equity is 0.30. bioAffinity Technologies' value of 0.38 is 26.7% above this benchmark. While the company's 10-year median is 0.12 vs. the industry median of 0.30, bioAffinity Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.30, based on 179 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. bioAffinity Technologies's current Debt-to-Equity of 0.38 is 26.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on bioAffinity Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. bioAffinity Technologies's current Debt-to-Equity is 0.38, which is 217% above median its own 10-year median of 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioAffinity Technologies stock overvalued right now?
bioAffinity Technologies (BIAFW) has a current Debt-to-Equity of 0.38. The current Debt-to-Equity is 0.38, which is 217% above median its 10-year median of 0.12 and 26.7% above the Medical Diagnostics & Research industry median of 0.30. bioAffinity Technologies' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For bioAffinity Technologies (BIAFW), the current Debt-to-Equity is 0.38 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
44GF Score
Get the complete analysis for BIAFW
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIAFW has been successfully added to your 
